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Introduction
Relapsed Extramedullary Multiple Myeloma 
Presenting as Bilateral Solid Perirenal Masses 
Thomas Rau and Aya Kamaya, M.D.
We present a patient with IgA myeloma who responded well to chemo-radiation therapy. The patient 
subsequently underwent autologous followed by nonmyeloablative allogenic bone marrow transplant 
and relapsed after six years in an unusual manner with extensive extramedullary disease with bilateral 
perirenal involvement. The highly variable expression of myeloma at relapse highlights the importance 
of individualized follow-up and periodic imaging for early detection of relapse.
Multiple myeloma is a neoplastic disorder caused by 
proliferation of B lymphocyte plasma cells that gives rise to 
a clone of immunoglobulin-secreting cells. Renal failure, 
osteolytic lesions, and hypercalcemia are typical and the re-
sult of overproduction of immunoglobulins and osteoclast 
activating factors by tumor cells. No curative treatment 
currently exists. Current trials with autologous hematopoi-
etic cell transplantation followed by nonmyeloablative 
allogeneic hematopoietic cell transplantation have been 
shown to reduce transplant related mortalities and provide 
longer disease free remissions [1]. Relapse typically mani-
fests as impairment of bone marrow function and increases 
in monoclonal antibodies (M-protein). However, relapse 
without a concomitant increase in M-protein has been 
reported and associated with poorly differentiated plasma 
cells and an aggressive clinical course [2]. Extramedullary 
plasmacytoma as a mode of relapse is highly unusual. To 
our knowledge, this is the first reported case of myeloma 
recurrence with extramedullary plasmacytoma and bilateral 
perirenal involvement after having undergone autologous 
and nonmyeloablative allogeneic hematopoietic cell trans-
plantation.
Case Report
A previously healthy 54-year-old man presented with 
a two-month history of low back pain which started after 
mild lifting. A work-up revealed an elevated total protein 
of 11.7 g/dL and serum protein electrophoresis with a 
beta-2 spike of 6.6 g/dL. A quantitative immunoglobulin 
test returned abnormal with an IgA of 6350, IgD of 404, 
and an IgM of 15 mg/dL. Diffuse osteopenia, multiple 
skull lucencies and one mid-humeral right 5 mm lucency 
were revealed by a metastatic bone survey. Further work-
up included an MRI that demonstrated T5, T12, and L2 
compression fractures and a bone marrow biopsy showed 
hypercellular marrow, trilineage hematopoiesis, and 50% 
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Figure 1A. 60-year-old man with relapsed multiple myeloma. 
CT demonstrates a small mass (short arrow) anterior to the 
stomach.
involvement with myeloma cells. The work up supported a 
diagnosis of stage IIIa IgA multiple myeloma.
Radiation therapy was instituted for vertebral lesions 
T12 through L2. Afterwards, he completed six cycles of 
vincristine, adriamycin, and dexamethasone chemotherapy 
and received thalidomide resulting in a reduction of his 
M-protein from 3.6 to 0.2 grams. A year later the patient 
underwent an autologous hematopoietic stem cell fol-
lowed by nonmyeloablative allogeneic cell transplant. His 
course following transplant was complicated by chronic 
graft-versus-host disease involving his mouth, eyes, skin, 
nails and esophagus. Symptoms were managed well with 
immunosupressive therapy though his course was compli-
cated by steroid induced diabetes, cataracts, and episodes 
of cytomegalovirus esophagitis. A bone marrow biopsy two 
years post-transplant confirmed that his myeloma was in 
remission.
After a six-and-a-half year disease-free period the 
patient re-presented at age 60 years with low back pain 
and increasing fatigue. He was found to be anemic and 
physical exam revealed a subcutaneous skin nodule on his 
back. A fine needle aspiration of the mass revealed plasma 
cells consistent with extramedullary plasmacytoma which 
was diagnostic for multiple myeloma relapse. CT showed 
bilateral perirenal masses (Fig. 1) not seen on previous 
imaging two years prior (Fig. 2). Paraspinal masses, a small 
mass anterior to the stomach, and subcutaneous masses 
with heterogeneous attenuation similar to the perirenal 
masses were also seen (Fig. 1). Given the biopsy results of 
the subcutaneous mass, its imaging similarities to the other 
masses, and their simultaneous appearance, the new lesions 
Figure 1B. CT demonstrates new perirenal mass (long ar-
row) and subcutaneous mass (arrowhead).
most likely represented extramedullary lesions rather than 
primary neoplasms and no further biopsies were per-
formed.
An elevated M-protein of 1.5 gms was measured and 
a bone marrow aspirate revealed trilineage hematopoiesis 
and left shifted myelopoiesis. Bone marrow biopsy showed 
less than 5% plasma cells but kappa light chain restric-
tion. These findings were consistent with relapsed multiple 
myeloma with progression to multiple extramedullary 
plasmacytomas. 
Figure 1C.  CT demonstrates bilateral perirenal masses (long ar-
rows) with heterogeneous attenuation.
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Discussion
The case described is of a patient with IgA multiple 
myeloma who responded well to radio-chemotherapy 
and underwent autologous followed by nonmyeloablative 
allogenic bone marrow transplant. He relapsed after six 
years with progression to multiple extramedullary plasma-
cytomas. Despite minimal clinical symptoms, the patient 
had developed widespread soft tissue tumors affecting both 
kidneys, abdomen, and subcutaneous space.
The development of gross extraosseous soft tissue 
masses is highly unusual except in the rare variant of IgD 
myeloma and is most striking in our patient’s mode of 
relapse [8]. An extensive literature search found only a few 
case reports of multiple myeloma progressing with similar 
features. Foucar, Davies, and Suchman each reported 
cases of multiple myeloma which progressed to extensive 
extramedullary disease at multiple sites and maintained 
anaplastic histologic features [2,4,5]. In our case, relapse 
was associated with widespread extramedullary mass le-
sions including bilateral perirenal masses and an immature 
plasma cell differentiation supporting the theory that an 
aggressive anaplastic variant of multiple myeloma may 
exist [2]. Interestingly, our patient was largely asymp-
tomatic at the time of relapse. Despite impressive wide-
spread mass lesions affecting both kidneys, our patient 
only complained of back pain and fatigue, and he denied 
any urinary symptoms. However, histologic grading has 
not always predicted the aggressiveness of the disease. 
Jowitt reported a case of multiple myeloma that relapsed 
Figure 2. MRI from two years prior to relapse showed only simple 
cysts bilaterally but no masses in the perirenal spaces.
with prominent extramedullary abdominal tumors and a 
fulminant course despite maintaining a well differentiated 
plasmacytoid form [6]. Thus, other factors that do not 
manifest histopathologically may determine the aggressive-
ness of the disease.
Extramedullary plasmacytoma is a rare variant of plasma 
cell tumors constituting about 3% of all cases as a primary 
lesion. It is distinguished from multiple myeloma by the 
absence of bone marrow infiltration, osteolytic lesions, 
hypercalcemia, renal insufficiency, and a urinary or serum 
M-protein level less than 2 g/dL. About 80% of lesions 
occur in the head and neck with localized disease whereas 
those occurring elsewhere including the gastrointestinal 
tract tend to present in a disseminated manner [3,10]. 
Though the plasma cell dyscrases are related, the clinical 
course and prognosis differ. This unusual variant tends to 
proceed with a more benign course with rare progression 
to multiple myeloma and a median survival of 10 years. 
The extramedullary lesions also tend to be controllable 
with surgical resection and local irradiation [7].
Our patient’s disease evolution is interesting in that its 
relapse was associated with bilateral solid perirenal masses 
as well as other solid masses, a pattern of spread usually 
seen in primary extramedullary plasmacytoma. However, 
the relatively benign nature of primary extramedullary 
plasmacytoma compared to that seen in extramedullary 
plasmacytoma during relapse of multiple myeloma suggests 
that these are different clinical entities.
Indeed, the pattern of relapse following treatment for 
multiple myeloma portends a different clinical course and 
prognosis. A recent study by Alegre et al studied 280 
patients with relapse after autologous peripheral stem 
cell transplant for multiple myeloma and found a very 
heterogeneous pattern of relapse [9]. Fourteen percent 
progressed with one or more extramedullary plasma-
cytomas, 18% were associated with an insidious rise 
in M-protein, 2% with plasmacytic leukemia, while 
the remaining 66% relapsed with classic myeloma 
with new osteolytic lesions. The authors speculate 
that these different modes of expression could be due 
to clonal selection following intensification therapy 
and the persistence of a resistant clone.
The highly variable modes of relapse follow-
ing treatment for multiple myeloma highlights the 
importance for an individualized approach for follow 
up monitoring. Since the elevation of M-protein and 
presence of clinical symptoms are unreliable indica-
tors of disease remission, the need for periodic imag-
ing may be necessary to detect early relapse. 
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